Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Eylea
Biotech
Innovent's anti-VEGF drug matches Eylea in eye disease trial
Innovent’s anti-VEGF drug held its own against Regeneron and Bayer’s blockbuster eye disease therapy Eylea in a phase 2 trial.
James Waldron
Mar 19, 2024 10:36am
Unity preps for Eylea battle following extended midstage test
Apr 24, 2023 10:25am
Kodiak asset matches Regeneron's Eylea in macular edema phase 3
Aug 8, 2022 9:53am
Another rival to Regeneron's Eylea struggles in phase 2
Mar 23, 2022 3:40pm
Kodiak's vision loss drug flops first of 6 phase 3 studies
Feb 23, 2022 10:00am
Roche's Eylea rival poised for FDA filings with new phase 3 data
Feb 12, 2021 9:05am
